分子缓解作为急性早幼粒细胞白血病的治疗目标
急性早幼粒细胞白血病(APL)以PML/RARA融合基因为特征,该标志物可用于诊断和微小残留病监测。大型随机试验表明ATRA联合ATO在疗效和安全性上优于传统ATRA加化疗。纵向PCR监测显示分子缓解与复发风险显著降低相关,而持续PCR阳性或由阴转阳与血液学复发强相关,专家小组推荐将分子缓解作为治疗目标。
要点
- PML/RARA融合基因是APL诊断和微小残留病监测的特异性生物标志物。
- ATRA联合ATO在新诊断APL中疗效和安全性优于传统ATRA加化疗。
- 巩固治疗后持续PCR阳性或随访中由阴转阳与血液学复发强相关。
核心结论
- 分子缓解(定义为PML/RARA的PCR检测转阴)与复发风险显著降低相关,而巩固治疗后持续PCR阳性或随访中由阴转阳与血液学复发强相关。
- 多个专家小组推荐将分子缓解视为APL的治疗目标,分子学反应已被现代临床试验采纳为研究终点。
研究设计与样本
- 综述性文章,汇总了大型临床研究(包括两项在新诊断APL患者中开展的随机试验)、口服砷剂和ATRA的初步研究、早期回顾性研究以及多项在临床试验入组的大队列APL患者中开展的前瞻性研究。
主要发现
- 两项在新诊断APL患者中开展的随机试验显示,ATRA-ATO联合方案在疗效和安全性方面均优于传统ATRA加化疗。
- 使用口服砷剂和ATRA制剂的初步研究提示,口服砷剂与静脉ATO同样有效且易于管理。
- 纵向PCR检测结果一致显示,分子缓解与复发风险显著降低相关。
- 巩固治疗后持续PML/RARA PCR阳性或随访中由阴性转为阳性与血液学复发强相关。
临床怎么用
- 基于上述数据,多个研究组对一线巩固治疗后持续PCR阳性或随访中由阴转阳的患者开始采用抢先挽救治疗。
- 多个专家小组推荐将分子缓解视为APL的治疗目标。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute promyelocytic leukemia (APL) is a subtype of acute leukemia characterized by a unique t(15;17) translocation generating the PML/RARA fusion gene and hybrid oncoprotein. Besides its critical role in leukemogenesis, this genetic aberration serves as a disease-specific biomarker for rapid diagnosis and monitoring of minimal residual disease (MRD). Moreover, PML/RARA is specifically targeted by All-trans retinoic acid (ATRA) and arsenic trioxide (ATO), two agents that synergistically act to induce degradation of the oncoprotein. Large clinical studies including two randomized trials conducted in newly diagnosed APL patients have shown that the ATRA-ATO combination is superior to conventional ATRA and chemotherapy both in terms of efficacy and safety. Preliminary studies using oral formulations of arsenic and ATRA suggest that oral arsenic is as effective and manageable as intravenous ATO. Following early retrospective studies indicating the prognostic relevance of PML/RARA monitoring, several prospective studies were conducted in large cohorts of APL patients enrolled in clinical trials with the aim of better assessing the prognostic value of longitudinal PCR testing. The results consistently showed that molecular remission (defined as negativization of the PCR test for PML/RARA) correlates with a significantly decreased risk of relapse, whereas persistence of PCR positivity for PML/RARA after consolidation or conversion from negative to positive during follow-up is strongly associated with hematologic relapse. Based on these data, various groups started using pre-emptive salvage therapy for patients who persisted PCR-positive after frontline consolidation or converted from negative to positive PCR during follow-up. Finally, several expert panels have recommended that molecular remission should be considered a therapeutic objective in APL, and molecular response has been adopted as a study endpoint in modern clinical trials.
引用
- Cicconi L, Fenaux P, Kantarjian H, et al. Molecular remission as a therapeutic objective in acute promyelocytic leukemia. Leukemia. 2018. PMID: 30026570. doi:10.1038/s41375-018-0219-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。